P
Peter D. Schellinger
Researcher at Ruhr University Bochum
Publications - 262
Citations - 18189
Peter D. Schellinger is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Stroke & Thrombolysis. The author has an hindex of 64, co-authored 240 publications receiving 15911 citations. Previous affiliations of Peter D. Schellinger include University Hospitals of the Ruhr-University of Bochum & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Grenzentscheidungen in der Schlaganfalltherapie
Matthias Endres,Martin Grond,Werner Hacke,Martin Ebinger,Peter D. Schellinger,Martin Dichgans +5 more
TL;DR: In this article, a number of such Grenzsituationen aufgedeckt and diskutiert are discussed, e.g., the Thrombolyse auserhalb geltender Zulassungskriterien (z.b. B. Vorhofflimmern and frischer Stent), or haufig diskuterten Risikokonstellationen (Demenz, Anamnese fur Sturze, Zustand nach intrazerebraler Blutung).
Journal ArticleDOI
Abstract 83: Successful Recanalization With Intravenous Thrombolysis Preceding Mechanical Thrombectomy in Large Vessel Occlusions: A Systematic Review and Meta-Analysis
Georgios Tsivgoulis,Aristeidis H. Katsanos,Peter D. Schellinger,Martin Köhrmann,Panayiotis N Varelas,Georgios Magoufis,M Paciaroni,Valeria Caso,Anne W. Alexandrov,Edip M Gurol,Andrei V Alexandrov +10 more
TL;DR: Pretreatment with intravenous thrombolysis in all eligible patients with emergent large vessel occlusion (ELVO) prior to mechanical thrombectomy with IVT is advocated.
Journal ArticleDOI
Hyperacute treatment of childhood stroke in Lyme neuroborreliosis: report of two cases and systematic review of the literature
Joerg Philipps,Bernhard Erdlenbruch,Michael Kuschnerow,Sunil Jagoda,Blerta Salihaj,Joerg Glahn,Peter D. Schellinger +6 more
TL;DR: Two children with acute stroke associated with LNB who underwent hyperacute stroke treatment are reported and LNB-associated infectious and inflammatory FCA is not a medical contraindication for reperfusion therapies in acute childhood stroke.
Journal ArticleDOI
Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.
Julia Krämer,Tanja Krömer-Olbrisch,Heinz-Jürgen Lakomek,Peter D. Schellinger,Dirk Foell,Sven G. Meuth,Vera Straeten +6 more
TL;DR: A patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still’s disease (AOSD) following alemtuzumab treatment is presented, highlighting AOSD as another rare and potentially life-threatening secondary autoinflammatory/autoimmune event following a LemtuzUMab treatment.
Journal ArticleDOI
Prolonged cardiac monitoring for stroke prevention: A systematic review and meta-analysis of randomized-controlled clinical trials
Georgios Tsivgoulis,Lina Palaiodimou,Sokratis Triantafyllou,Martin Köhrmann,Polychronis Dilaveris,Constantinos Tsioufis,Gkikas Magiorkinis,Christos Krogias,Peter D. Schellinger,Valeria Caso,Maurizio Paciaroni,Mukul Sharma,Robin Lemmens,David J. Gladstone,Tommaso Sanna,Rolf Wachter,Gerasimos Filippatos,Aristeidis H. Katsanos +17 more
TL;DR: In this article , a systematic review and meta-analysis, randomized-controlled clinical trials (RCTs) reporting IS rates among patients with known cardiovascular risk factors, including but not limited to history of ischemic stroke, who received PCM for more than 7 days versus more conservative cardiac rhythm monitoring methods were pooled.